While immune checkpoint inhibitors (ICIs), targeting PD-1 (programmed cell death protein 1), PD-L1 (Programmed Death-Ligand 1), and CTLA-4 (cytotoxic T-lymphocyte antigen-4), have become standard care for advanced NSCLC without actionable mutations [21], their effectiveness in EGFRm NSCLC is limited, with low response rates [22,23,24,25], which are associated with toxicity [26,27]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.